LUMAKRAS (sotorasib)
ORAL TREATMENTS FOR NON-SMALL CELL LUNG CANCER·NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION·+1
AMGEN
Indication
Non-small cell lung cancer with KRAS G12C mutation
Non-small cell lung cancer with KRAS G12C mutation refers to a biologically distinct molecular subset of malignant epithelial lung tumors, primarily lung adenocarcinomas, affecting the respiratory system. Read more about Non-small cell lung cancer with KRAS G12C mutation
2 drugs 2 manufacturers
Drugs that treat it
Common Non-small cell lung cancer with KRAS G12C mutation therapies.
KRAZATI (adagrasib)
ORAL TREATMENTS FOR NON-SMALL CELL LUNG CANCER·NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION
MIRATI THERAPEU
Filter & compare in the drug finder →Opens the drug finder with Non-small cell lung cancer with KRAS G12C mutation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNon-small cell lung cancer with KRAS G12C mutation refers to a biologically distinct molecular subset of malignant epithelial lung tumors, primarily lung adenocarcinomas, affecting the respiratory system.
It is defined by a somatic missense mutation in codon 12 of the KRAS proto-oncogene, substituting glycine with cysteine.
Pathophysiologically, this alteration impairs intrinsic GTP hydrolysis, locking the KRAS GTPase into a constitutively active state that persistently stimulates downstream MAPK/ERK and PI3K/AKT intracellular signaling pathways.
This unrestrained signaling promotes dysregulated cellular proliferation, survival, and tumor progression, representing an actionable oncogenic driver alteration in precision oncology.
- nih.gov
Non-small cell lung cancer with KRAS G12C mutation refers to a biologically distinct molecular subset of malignant epithelial lung tumors, primarily lung adenocarcinomas, affecting the respiratory system It is defined by a somatic missense mutation in codon 12 of the KRAS proto-oncogene, substituting glycine with cysteine
- imrpress.com
Non-small cell lung cancer with KRAS G12C mutation refers to a biologically distinct molecular subset of malignant epithelial lung tumors, primarily lung adenocarcinomas, affecting the respiratory system
- nih.gov
It is defined by a somatic missense mutation in codon 12 of the KRAS proto-oncogene, substituting glycine with cysteine
- nih.gov
Pathophysiologically, this alteration impairs intrinsic GTP hydrolysis, locking the KRAS GTPase into a constitutively active state that persistently stimulates downstream MAPK/ERK and PI3K/AKT intracellular signaling pathways This unrestrained signaling promotes dysregulated cellular proliferation, survival, and tumor progression, representing an actionable oncogenic driver alteration in precision oncology
- oncokb.org
Pathophysiologically, this alteration impairs intrinsic GTP hydrolysis, locking the KRAS GTPase into a constitutively active state that persistently stimulates downstream MAPK/ERK and PI3K/AKT intracellular signaling pathways
- mypathologyreport.ca
Pathophysiologically, this alteration impairs intrinsic GTP hydrolysis, locking the KRAS GTPase into a constitutively active state that persistently stimulates downstream MAPK/ERK and PI3K/AKT intracellular signaling pathways This unrestrained signaling promotes dysregulated cellular proliferation, survival, and tumor progression, representing an actionable oncogenic driver alteration in precision oncology
Personalize your experience
Follow Non-small cell lung cancer with KRAS G12C mutation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.